Progenity Announces Closing of the Convertible Senior Notes Offering and Partial Exercise of the Initial Purchaser’s Option to Purchase Additional Notes
08 déc. 2020 07h31 HE
|
Progenity, Inc.
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Announces Closing of Public Offering of Common Stock
08 déc. 2020 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing...
Progenity, Inc. Prices $75.0 Million Convertible Senior Notes Offering
02 déc. 2020 23h51 HE
|
Progenity, Inc.
SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG) today announced the pricing of its offering of $75.0 million aggregate principal amount of 7.25% convertible senior notes...
Progenity Announces Pricing of Public Offering of Common Stock
02 déc. 2020 23h50 HE
|
Progenity, Inc.
SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing...
Progenity Announces Proposed Convertible Senior Notes Offering
30 nov. 2020 21h39 HE
|
Progenity, Inc.
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG) today announced its intention to offer, subject to market and other conditions, $75 million aggregate principal amount of...
Progenity Announces Proposed Public Offering of Common Stock
30 nov. 2020 21h38 HE
|
Progenity, Inc.
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing...
New Test for Triaging Preeclampsia Passes Key Development Milestone: Progenity Releases Prospective Clinical Verification Data for its Preecludia™ Test
20 nov. 2020 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity to Present at 2020 San Antonio Breast Cancer Virtual Symposium
17 nov. 2020 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity to Participate in the 32nd Annual Piper Sandler Healthcare Conference
16 nov. 2020 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity to Host Preeclampsia Virtual R&D Day on November 20, 2020
13 nov. 2020 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...